guanfacine has been researched along with Lassitude in 5 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether treatment with guanfacine extended release (GXR) in subjects with attention-deficit/hyperactivity disorder (ADHD) disrupted psychomotor functioning and alertness, or impacted daytime sleepiness." | 5.15 | Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. ( Farrand, K; Kollins, SH; López, FA; Lyne, A; Roth, T; Turnbow, JM; Vince, BD; Wigal, SB, 2011) |
| "Estulic (guanfacine), a new centrally acting antihypertensive agent derived from guanidine, was administered to 13 patients with established essential hypertension." | 3.66 | [Estulic in the long-term treatment of hypertension]. ( Rhomberg, F, 1980) |
| "Guanfacine is a noradrenergic agonist that is believed to improve symptoms of attention-deficit/hyperactivity disorder (ADHD) through selective actions at alpha2A-adrenoceptors in the prefrontal cortex." | 2.73 | Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. ( Biederman, J; Donahue, J; Lyne, A; McBurnett, K; Melmed, RD; Patel, A, 2008) |
| " This report documents the time course and predictors of symptom efficacy and sedation-related adverse events (AEs) that emerge during GXR treatment throughout 3 randomized, placebo-controlled, double-blind trials of the drug." | 1.36 | Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. ( Faraone, SV; Glatt, SJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biederman, J | 1 |
| Melmed, RD | 1 |
| Patel, A | 1 |
| McBurnett, K | 1 |
| Donahue, J | 1 |
| Lyne, A | 2 |
| Faraone, SV | 1 |
| Glatt, SJ | 1 |
| Rostain, AL | 1 |
| Kollins, SH | 1 |
| López, FA | 1 |
| Vince, BD | 1 |
| Turnbow, JM | 1 |
| Farrand, K | 1 |
| Wigal, SB | 1 |
| Roth, T | 1 |
| Rhomberg, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT00150592] | Phase 2 | 182 participants (Actual) | Interventional | 2005-05-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00150592)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a Scale (Mean) |
|---|---|
| SPD503 | -8.8 |
| Placebo | -5.5 |
Choice reaction time (CRT) is a computerized assessment that trains the subject in holding down a press-pad and releasing the press-pad in response to stimuli presented on the screen. The task requires the subject to react as soon as a yellow dot appears in one of five locations, and the subject must respond by lifting their hand from the press-pad. This is the reaction time (RT) and ranges from 100 to 5000 msec. Lower scores indicate better performance. (NCT00150592)
Timeframe: Baseline and 6 weeks
| Intervention | msec (Mean) |
|---|---|
| SPD503 | 20.7 |
| Placebo | 21.9 |
The Digital Symbol Substitution Task/Coding Test (DSST/Coding) assesses relative contributions of speed, memory, and visual scanning. Subjects are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time. Scores range from 0-65 in age category 6-7 years and 0-199 in age category 8-17 years. Higher scores indicate better performance. (NCT00150592)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD503 | 18.3 |
| Placebo | 20.7 |
The Digital Symbol Substitution Task/Coding Test (DSST/Coding) assesses relative contributions of speed, memory, and visual scanning. Subjects are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time. Scores range from 0-65 in age category 6-7 years and 0-199 in age category 8-17 years. Higher scores indicate better performance. (NCT00150592)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD503 | 1.9 |
| Placebo | 9.7 |
The Pediatric Daytime Sleepiness Scale (PDSS) is an 8 question questionnaire scored on a scale from 0 (never) to 4 (always). Total scores range from 0 to 32, with increasing score reflecting greater sleepiness. (NCT00150592)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a Scale (Mean) |
|---|---|
| SPD503 | -1.3 |
| Placebo | 0.9 |
The Pictorial Sleepiness Scale (PSS) scores range from 1 (far left wide awake face) to 5 (far right very sleepy face). Increasing score reflects greater sleepiness. (NCT00150592)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a Scale (Mean) |
|---|---|
| SPD503 | 0.0 |
| Placebo | 0.1 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00150592)
Timeframe: 6 weeks
| Intervention | Participants (Number) |
|---|---|
| SPD503 | 67 |
| Placebo | 20 |
"The Spatial Working Memory (SWM) Test is a computerized assessment of working memory and strategy performance. The subject is required to find blue tokens in various displayed boxes and use the tokens to fill a column on the right side of the screen. Subjects can only find tokens in new boxes, therefore they must remember where previous tokens were found. SWM scores including number of between errors, number of within errors, and number of double errors range 0-800 and SWM strategy scores range 8-56. Lower scores indicate better performance." (NCT00150592)
Timeframe: Baseline and 6 weeks
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Between errors | Within errors | Double errors | Strategy | |
| Placebo | -3.2 | -0.1 | 0.1 | -0.1 |
| SPD503 | -4.4 | 0.0 | -0.0 | -0.9 |
3 trials available for guanfacine and Lassitude
| Article | Year |
|---|---|
Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2008 |
Guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder.
Topics: Abdominal Pain; Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity | 2009 |
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Chi | 2011 |
2 other studies available for guanfacine and Lassitude
| Article | Year |
|---|---|
Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Child; Delayed | 2010 |
[Estulic in the long-term treatment of hypertension].
Topics: Adult; Blood Pressure; Fatigue; Female; Guanfacine; Guanidines; Humans; Hypertension; Long-Term Care | 1980 |